These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 20649837

  • 1. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
    Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE.
    J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
    Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
    [Abstract] [Full Text] [Related]

  • 4. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
    Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
    [Abstract] [Full Text] [Related]

  • 5. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.
    Farnsworth SJ, Volz TJ, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2009 Mar; 328(3):807-12. PubMed ID: 19038779
    [Abstract] [Full Text] [Related]

  • 6. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.
    Eyerman DJ, Yamamoto BK.
    J Neurochem; 2007 Nov; 103(3):1219-27. PubMed ID: 17683483
    [Abstract] [Full Text] [Related]

  • 7. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
    Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ, Adair BP, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
    [Abstract] [Full Text] [Related]

  • 8. A single methamphetamine administration rapidly decreases vesicular dopamine uptake.
    Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2002 Aug; 302(2):497-501. PubMed ID: 12130707
    [Abstract] [Full Text] [Related]

  • 9. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
    Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
    [Abstract] [Full Text] [Related]

  • 10. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
    Eyerman DJ, Yamamoto BK.
    J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
    [Abstract] [Full Text] [Related]

  • 11. Methamphetamine rapidly decreases vesicular dopamine uptake.
    Brown JM, Hanson GR, Fleckenstein AE.
    J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
    [Abstract] [Full Text] [Related]

  • 12. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.
    J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
    [Abstract] [Full Text] [Related]

  • 13. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
    Brown JM, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
    [Abstract] [Full Text] [Related]

  • 16. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
    Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.
    Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2009 Apr; 329(1):169-74. PubMed ID: 19141713
    [Abstract] [Full Text] [Related]

  • 18. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
    Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE.
    Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873
    [Abstract] [Full Text] [Related]

  • 19. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
    Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):68-73. PubMed ID: 19326567
    [Abstract] [Full Text] [Related]

  • 20. Methamphetamine-induced alterations in dopamine transporter function.
    Bennett BA, Hollingsworth CK, Martin RS, Harp JJ.
    Brain Res; 1998 Jan 26; 782(1-2):219-27. PubMed ID: 9519266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.